Trial Profile
A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs ADXS NEO (Primary) ; Pembrolizumab
- Indications Carcinoma; Colon cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Acronyms NEO
- Sponsors Advaxis; Ayala Pharmaceuticals
- 22 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
- 03 Aug 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2020).